Wedbush Upgrades Arcus Biosciences Ahead of Key 2026 Clinical Data
Wedbush upgraded Arcus Biosciences with a new $41 price target and added the stock to its Best Ideas List ahead of major 2026 clinical updates for casdatifan in kidney cancer.
NOTRELOAD AI
FDA Fast Track Boosts Context Therapeutics’ CTIM-76 for Hard-to-Treat Ovarian Cancer
Context Therapeutics’ CTIM-76 wins FDA Fast Track Designation for platinum-resistant ovarian cancer. Phase 1a trial ongoing with interim data expected in June 2026.
Tesla’s Weakest Quarter in Years: Deliveries Miss Expectations
Tesla’s Q1 sales fell short, EV demand slows, older models lag, but investors watch robotaxis and AI plans.
Immunovant’s Batoclimab Flops in Phase 3 Thyroid Eye Disease Trials
Immunovant’s batoclimab failed key TED trials, but high doses helped; focus now shifts to next-gen drug IMVT-1402 for autoimmune disease.
Rivian Delivers 10,365 Vehicles in Q1 2026 – Beats Analyst Forecasts
Rivian beat Q1 delivery forecasts, demand is stabilizing, and a cheaper R2 model plus an Uber deal could boost future growth.
Cocrystal Pharma Gets FDA Fast Track for Norovirus Treatment & Prevention
FDA fast-tracks a new oral drug, CDI-988, to treat and prevent norovirus—a common stomach virus affecting millions worldwide.